Get the full details on Vyglxia now. FDA accepts Biohaven's resubmitted troriluzole NDA for spinocerebellar ataxia (SCA), ...

Notre Dame researchers identify a TfR1 dimer that rises during ferroptosis, detectable in tissue and blood. Read the full study findings to learn more now.

Menarini's Stemline licenses GIM-621, a first-in-class oral immuno-oncology agent from Georgiamune, in a deal worth up to $1.1B. Read the full story now.

Stanford's AI digital twin predicts aspirin plus lansoprazole could delay labor about 15 times longer than aspirin alone.

Columbia researchers reveal how PARG inhibitors trap DNA-repair proteins to kill cancer cells, pointing to a possible ...

Olorofim meets its non-inferiority goal against AmBisome in the Phase III OASIS trial for invasive aspergillosis. Read full ...

Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...

Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...

Kyverna reports one-year Phase II data for miv-cel in stiff person syndrome and plans a rolling BLA filing. Read the full ...

Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...

City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...

Curis prices an $8.5M private placement at $0.51 per share to fund emavusertib CLL data in December 2026. Read the full story on the offering and runway.